Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'- difluoro-2'-deoxycytidine (gemcitabine)

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 3, 2000, Pages 785-791

  Fields, Marc T ^a   Eisbruch, Avraham ^a   Normolle, Daniel ^a   Orfali, Anas ^a   Davis, Mary A ^a   Pu, Anthony T ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

2'2' difluoro 2' deoxycytidine; Gemcitabine; Head and neck cancer; Radiation sensitizing agent

Indexed keywords

GEMCITABINE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HEAD AND NECK CANCER; MOUSE; MOUTH MUCOSA; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BODY WEIGHT; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEAD AND NECK NEOPLASMS; LIP; MICE; MICE, INBRED C3H; MOUTH MUCOSA; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; WEIGHT LOSS;

EID: 0034214240     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00447-8     Document Type: Article

References (36)

1. Moore M., Andersen J., Burris H., et al. A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. (Meeting abstract) Proc Annu Meet Am Soc Clin Oncol. 14:1995;A473.
2. Rothenberg M.L., Moore M.J., Cripps M.D., et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 14:1996;347.
3. Hoffman J., McGinn C., Szarka C., et al. A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol. 17:1998;283a.
4. McGinn C., Smith D., Szarka C., et al. A phase I study of gemcitabine in combination with radiation therapy in patients with localized unresectable pancreatic cancer. Proc Am Soc Clin Oncol. 17:1998;264a.
5. Blackstock A., Bernard S., Richards F., et al. Phase I study of concurrent radiation and twice-weekly gemcitabine in advanced/metastatic pancreatic cancer. Proc Am Soc Clin Oncol. 17:1998;264a.
6. Le Chevalier T. Single-agent activity of gemcitabine in advanced non-small cell lung cancer. Semin Oncol. 23:1996;36-42.
7. Steward W., Dunlop D., Dabouis G., et al. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer Preliminary results . Semin Oncol. 23:1996;43-47.
8. Shepherd F., Burkes R., Cormier Y., et al. Final results of the Canadian phase I dose escalation trail of gemcitabine and cisplatin for advanced non-small cell lung cancer. Semin Oncol. 23:1996;48-54.
9. Carmichael J., Allerheiligen S., Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol. 23:1996;55-59.
10. Abratt R., Bezwoda W., Falkson G., et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer A phase II study . J Clin Oncol. 12:1994;1535-1540.
11. Anderson H., Lund B., Bach F., et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer A phase II study . J Clin Oncol. 12:1994;1821-1826.
12. Eisbruch A., Shewach D., Urba S., et al. Phase I trail of radiation (RT) concurrent with low dose gemcitabine (GEM) for head and neck cancer High mucosal and pharyngeal toxicity . Am Soc Clin Oncol. 16:1997;386A.
13. Heinemann V., Hertel L.W., Grindey G.B., et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031.
14. Baker C.H., Banzon J., Bollinger J.M., et al. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates Potent mechanism-based inhibitors of ribonucleotide reductase . J Med Chem. 34:1991;1879-1884.
15. Shewach D.S., Hahn T.M., Chang E., et al. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54:1994;3218-3223.
16. Huang P., Chubb S., Hertel L.W., et al. Action of 2′,-2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
17. Ruiz van Halperin V.W.T., Veerman G., Vermorken J.B., et al. 2′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 46:1993;762-766.
18. Rockwell S., Grindey G.B. Effect of 2,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res. 4:1992;151-155.
19. Shewach D., Lawrence T. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol Suppl. 22:1995;68-71.
20. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 34:1996;867-872.
21. McGinn C.J., Shewach D.S., Lawrence T.S. Radiosensitizing nucleosides. JNCI. 88:1996;1193-1203.
22. Lawrence T.S., Change E.Y., Hahn T.M., et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′, 2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res. 3:1997;777-782.
23. Lawrence T.S., Eisbruch A., Shewach D. Gemcitabine-mediated radiosensitization. Semin Oncol Suppl. 24:1997;24-28.
24. Braakhuis B., Ruiz van Halperin V., Boven E., et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol. 122:1995;42-46.
25. Xu F., van der Schuren E., Ang K. Acute reactions of the lip mucosa of mice to fractionated irradiations. Radiother Oncol. 1:1984;369-374.
26. Baker S.R. An in vivo model for squamous cell carcinoma of the head and neck. Laryngoscope. 95:1985;43-56.
27. Joschko M.A., Webster L.K., Groves J., et al. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Investig. 5:1997;62-71.
28. Milas L., Fujii T., Hunter N., et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 59:1999;107-114.
29. Latz D., Fleckenstein K., Eble M., et al. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys. 41:1998;875-882.
30. Gregoire V., Beauduin M., Bruniaux M., et al. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol. 73:1998;511-520.
31. Huang P., Robertson L., Wright S., et al. High molecular weight DNA fragmentation A critical event in nucleoside analogue-induced apoptosis in leukemia cells . Clin Cancer Res. 1:1995;1005-1013.
32. McGinn C.J., Shureiqi I., Robertson J.M., et al. A phase I trial of radiation dose escalation with full dose gemcitabine (GEM) in patients (pts) with pancreatic cancer. Proc ASCO. 18:1999;274a.
33. Merlano M., Benasso M., Corvo R. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. JNCI. 88:1996;583-589.
34. Brizel D., Albers M., Fisher S., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 338:1998;1798-1804.
35. Munro A. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 71:1995;83-91.
36. Al-Sarraf M., LeBlanc M., Giri P., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer Phase III randomized Intergroup study 0099 . Clin Oncol. 16:1998;1310-1317.